Pyxis Oncology Stock Number Of Shares Shorted
| PYXS Stock | USD 1.15 0.05 4.17% |
Pyxis Oncology fundamentals help investors to digest information that contributes to Pyxis Oncology's financial success or failures. It also enables traders to predict the movement of Pyxis Stock. The fundamental analysis module provides a way to measure Pyxis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pyxis Oncology stock.
Pyxis | Number Of Shares Shorted |
Pyxis Oncology Company Number Of Shares Shorted Analysis
Pyxis Oncology's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Pyxis Oncology Number Of Shares Shorted | 6.88 M |
Most of Pyxis Oncology's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pyxis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pyxis Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Pyxis Oncology is extremely important. It helps to project a fair market value of Pyxis Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Pyxis Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pyxis Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pyxis Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Pyxis Oncology has 6.88 M of outstending shares currently sold short by investors. This is 114.93% higher than that of the Biotechnology sector and 34.9% higher than that of the Health Care industry. The number of shares shorted for all United States stocks is 46.14% lower than that of the firm.
Pyxis Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pyxis Oncology's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pyxis Oncology could also be used in its relative valuation, which is a method of valuing Pyxis Oncology by comparing valuation metrics of similar companies.Pyxis Oncology is currently under evaluation in number of shares shorted category among its peers.
Pyxis Oncology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pyxis Oncology from analyzing Pyxis Oncology's financial statements. These drivers represent accounts that assess Pyxis Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pyxis Oncology's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 445.6M | 78.9M | (116.1M) | 83.5M | 91.9M | 87.3M |
Pyxis Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (4.06) % | ||||
| Current Valuation | (35.9 M) | ||||
| Shares Outstanding | 61.59 M | ||||
| Shares Owned By Insiders | 23.72 % | ||||
| Shares Owned By Institutions | 40.08 % | ||||
| Number Of Shares Shorted | 6.88 M | ||||
| Price To Book | 0.59 X | ||||
| Price To Sales | 4.58 X | ||||
| Revenue | 16.15 M | ||||
| Gross Profit | 15.67 M | ||||
| EBITDA | (65.51 M) | ||||
| Net Income | (77.33 M) | ||||
| Cash And Equivalents | 223.36 M | ||||
| Cash Per Share | 7.48 X | ||||
| Total Debt | 20.2 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 15.19 X | ||||
| Book Value Per Share | 2.01 X | ||||
| Cash Flow From Operations | (57.67 M) | ||||
| Short Ratio | 10.14 X | ||||
| Earnings Per Share | (1.32) X | ||||
| Price To Earnings To Growth | 0.01 X | ||||
| Target Price | 6.8 | ||||
| Number Of Employees | 44 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 73.91 M | ||||
| Total Asset | 157.18 M | ||||
| Retained Earnings | (363.56 M) | ||||
| Working Capital | 114.76 M | ||||
| Net Asset | 157.18 M |
About Pyxis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pyxis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pyxis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pyxis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.